|
Catalogue Number
|
152542 |
|
Applications
|
WB
|
|
Antigen/Gene or Protein Targets
|
ADAM17
|
|
Reactivity
|
Mouse
|
|
Relevance
|
ADAM17 (TACE/CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.
|
|
Host
|
Rabbit
|
|
Immunogen
|
Pro-domain of murine ADAM17
|
|
Formulation
|
Whole serum
|
|
Molecular Weight (kDa)
|
~120
|
|
Notes
|
Suggested dilution for western blot: 1:250
|
|
Research Area
|
Cancer, Cell Signaling & Signal Transduction, Metabolism, Neurobiology, Stem Cell Biology
|
![Image thumbnail for Anti-ADAM17, Polyclonal [17MOPRO]](https://res.cloudinary.com/ximbio/image/upload/c_fit,h_45/3eb74762-21cf-4da2-ba48-4f1c73a6ee51.jpg)
